Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lo

Showing results (381-390 of 386) with videos related to

Pageof 39
Sort By:
You have reached the last page of results.This site can display upto 386 results.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaPrachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanomaP Grover, S N Lo, I Li, et al.
The New England Journal of Medicine|June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaChristian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Pageof 39

Showing results (381-390 of 386) with videos related to

Sort By:
Pageof 39
You have reached the last page of results.This site can display upto 386 results.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaPrachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanomaP Grover, S N Lo, I Li, et al.
The New England Journal of Medicine|June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaChristian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Pageof 39